MCID: DNG003
MIFTS: 68

Dengue Disease

Categories: Rare diseases, Infectious diseases, Genetic diseases

Aliases & Classifications for Dengue Disease

MalaCards integrated aliases for Dengue Disease:

Name: Dengue Disease 38 12 15
Dengue Fever 12 76 53 3 73
Dengue 55 43 44
Dengue Shock Syndrome 53 73
Df 53 3
Philippine Hemorrhagic Fever 53
Singapore Hemorrhagic Fever 53
Dengue Hemorrhagic Fever 53
Dengue Virus Infection 53
Thai Hemorrhagic Fever 53
Hemorrhagic Dengue 53
Classical Dengue 12
Breakbone Fever 12
Classic Dengue 12
Severe Dengue 73

Classifications:



Summaries for Dengue Disease

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 99828Disease definitionDengue fever (DF), caused by dengue virus, is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leakage and hemorrhage (dengue hemorrhagic fever, or DHF) and shock (dengue shock syndrome, or DSS).EpidemiologyDF is found in the tropics worldwide, especially in Southeast Asia, the Pacific region, and the Americas, with 40% of the global population at risk. An estimated 50 to 100 million cases of DF, 500,000 hospitalizations, and 20,000 deaths occur yearly worldwide.Clinical descriptionThe vast majority of dengue virus infections result in DF, which is characterized by sudden onset of fever, malaise, headache (classically retro-orbital), and myalgia/arthralgia, often followed soon after by a petechial rash, which may be pruritic. In most cases, symptoms will resolve within 7 days without further complications. However, in a small minority of patients, a brief period of deffervescence is followed by worsening abdominal symptoms (pain, nausea, vomiting, diarrhea), thrombocytopenia, hemorrhage (DHF: epistaxis, bleeding gums, gastrointestinal bleeding) and a capillary leak syndrome (DSS: hemoconcentration, hypoalbuminemia, pleural effusion, shock). DHF/DSS are seen most often in children under the age of 15 years. Risk is greater with secondary heterologous infection by one of the four dengue virus serotypes, but severe disease may be seen with first infections.EtiologyOver 25 different viruses cause viral hemorrhagic fever. Dengue virus belongs to the Flaviviridae family, genus Flavivirus. Four distinct serotypes, with significant strain variation, are recognized. Dengue viruses are maintained in humans and transmitted between them by the bite of infected mosquitoes, most commonly Aedes aegypti but also Aedes albopictus). Person-to-person transmission has not been reported.Diagnostic methodsCommon diagnostic modalities include serologic testing by enzyme linked immunosorbent assay (ELISA) and reverse transcriptionpolymerase chain reaction (RT-PCR). Virus isolation may also be performed in specialized laboratories. The viremic phase of DF/DHF is usually brief (first 3-5 days of illness), after which time detection of anti-dengue IgM antibodies, which appear as early as 2-4 days after disease onset, is the mainstay. Numerous commercial ELISA assays are available with varying degrees of sensitivity and specificity.Differential diagnosisDF is difficult to distinguish from a host of other febrile illnesses such as malaria and typhoid fever (see these terms), especially early in the course of disease before the rash appears. For DHF/DSS, other viral hemorrhagic fevers, leptospirosis, rickettsial infection (see these terms) and meningococcemia need to be excluded.Management and treatmentAs there is presently no antiviral drug available for DF/DHF, treatment is supportive, following the guidelines for treatment of severe septicemia. Insecticide-treated bed nets, room screens and elimination of larval development sites should be used in open-air settings to prevent further transmission.PrognosisCase-fatality rates for DF are less than 1% but may rise to as high as 40% in DHF/DSS, largely dependent upon whether access to advanced medical care exists. Children and persons with underlying chronic diseases such as diabetes, heart disease, and asthma are at increased risk. The most severe phase of disease usually lasts only a few days and survivors generally have no lasting sequelae.Visit the Orphanet disease page for more resources.

MalaCards based summary : Dengue Disease, also known as dengue fever, is related to dengue hemorrhagic fever and dengue shock syndrome, and has symptoms including fever and pruritus. An important gene associated with Dengue Disease is NEAT1 (Nuclear Paraspeckle Assembly Transcript 1
We identified Nuclear Enriched Abundant Transcript 1 (NEAT1) as one of the differentially expressed lncRNAs (adjusted P ? 0.05 and log-fold change ? 2) and subsequently validated the expression by qRT-PCR. The co-expression analysis further revealed that NEAT1 and the coding gene IFI27 were highly co-expressed and negatively correlated with dengue severity. Using regression analysis, we observed that NEAT1 expression was significantly dependent on disease progression (Coefficient = -0.27750, SE Coefficient = 0.07145, and t = -3.88).Further, receiver operating characteristic (ROC) curve revealed that NEAT1 expression could discriminate DI from DS (sensitivity and specificity of 100% (95%CI: 85.69 - 97.22) and area under the curve (AUC) = 0.97).
Dysfunction Pattern: Expression [differentially expressed]), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Ketotifen and Histamine have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone, and related phenotypes are gingival bleeding and epistaxis

MedlinePlus : 43 Dengue is an infection caused by a virus. You can get it if an infected mosquito bites you. Dengue does not spread from person to person. It is common in warm, wet areas of the world. Outbreaks occur in the rainy season. Dengue is rare in the United States. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from your nose, gums, or under your skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. These forms of dengue are life-threatening. There is no specific treatment. Most people with dengue recover within 2 weeks. Until then, drinking lots of fluids, resting and taking non-aspirin fever-reducing medicines might help. People with the more severe forms of dengue usually need to go to the hospital and get fluids. To lower your risk when traveling to areas where dengue is found Wear insect repellent with DEET Wear clothes that cover your arms, legs and feet Close unscreened doors and windows NIH: National Institute of Allergy and Infectious Diseases

CDC : 3 Get Email Updates

Disease Ontology : 12 A viral infectious disease that results in infection, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom fever, has symptom severe headache, has symptom severe pain behind the eyes, has symptom joint pain, has symptom muscle and bone pain, has symptom rash, and has symptom mild bleeding.

Wikipedia : 76 Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin... more...

Related Diseases for Dengue Disease

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 dengue hemorrhagic fever 10.9
2 dengue shock syndrome 10.9
3 asymptomatic dengue 10.9
4 lymphocytic vasculitis 10.8 ICAM1 VCAM1
5 cortical thymoma 10.8 ICAM1 VCAM1
6 immunoglobulin g deficiency 10.8 CD40LG MBL2
7 acquired thrombocytopenia 10.8 IL11 THPO
8 mooren's ulcer 10.7 ICAM1 VCAM1
9 heterophyiasis 10.7 CD40LG ICAM1
10 coccidioidomycosis 10.7 CD40LG MBL2
11 secondary syphilis 10.6 CD209 CD40LG
12 subendocardial myocardial infarction 10.6 ICAM1 VCAM1
13 african tick-bite fever 10.6 CCL5 CD40LG
14 actinic prurigo 10.6 ICAM1 VCAM1
15 rift valley fever 10.6 CD209 CD40LG
16 thrombocytopenia due to platelet alloimmunization 10.6 CD40LG THPO
17 trichostrongyloidiasis 10.6 CD40LG PIK3C2A
18 ornithosis 10.5 CD40LG PIK3C2A
19 henoch-schoenlein purpura 10.5 CD40LG ICAM1 VCAM1
20 cytomegalovirus infection 10.5 CCL5 ICAM1 VCAM1
21 oral lichen planus 10.5 CCL5 ICAM1 VCAM1
22 autoinflammation, lipodystrophy, and dermatosis syndrome 10.5 CCL5 ICAM1 VCAM1
23 trypanosomiasis 10.4 CCL5 ICAM1 VCAM1
24 zika fever 10.4 CD40LG RAF1
25 vasculitis 10.4 CD40LG ICAM1 VCAM1
26 kyasanur forest disease 10.4 CD40LG RAF1
27 severe acute respiratory syndrome 10.4 CCL5 CD209 CD40LG
28 rhinitis 10.4 CCL5 ICAM1 VCAM1
29 splenic disease 10.4 CD40LG THPO
30 trichinosis 10.4 CD40LG PIK3C2A
31 relapsing-remitting multiple sclerosis 10.4 CCL5 ICAM1 NEAT1
32 glomerulonephritis 10.4 CD40LG ICAM1 VCAM1
33 respiratory system disease 10.4 CCL5 CD40LG ICAM1
34 idiopathic neutropenia 10.4 CCL5 CD40LG THPO
35 demyelinating disease 10.3 CCL5 CD40LG ICAM1
36 chronic eosinophilic pneumonia 10.3 CCL5 ICAM1
37 viral infectious disease 10.3 CCL5 CD209 CD40LG
38 chylothorax, congenital 10.3 PTPN11 VCAM1
39 immunoglobulin alpha deficiency 10.3 CD40LG MBL2
40 murray valley encephalitis 10.2 CD40LG RAF1
41 lentigines 10.2 PTPN11 RAF1
42 noonan syndrome with multiple lentigines 10.1 PTPN11 RAF1
43 shwartzman phenomenon 10.1 FCGR1A ICAM1 VCAM1
44 acute proliferative glomerulonephritis 10.1 CD40LG ICAM1
45 bone marrow cancer 10.1 IL11 PTPN11 THPO
46 immune-complex glomerulonephritis 10.0 ICAM1 VCAM1
47 pneumonia 9.9 CCL5 CD40LG MBL2 PIK3C2A
48 dengue virus 9.9
49 hematologic cancer 9.9 CD40LG IL11 PTPN11 THPO
50 endotheliitis 9.7

Graphical network of the top 20 diseases related to Dengue Disease:



Diseases related to Dengue Disease

Symptoms & Phenotypes for Dengue Disease

Human phenotypes related to Dengue Disease:

32 (show all 22)
# Description HPO Frequency HPO Source Accession
1 gingival bleeding 32 occasional (7.5%) HP:0000225
2 epistaxis 32 occasional (7.5%) HP:0000421
3 petechiae 32 occasional (7.5%) HP:0000967
4 bruising susceptibility 32 occasional (7.5%) HP:0000978
5 skin rash 32 frequent (33%) HP:0000988
6 pruritus 32 frequent (33%) HP:0000989
7 lethargy 32 occasional (7.5%) HP:0001254
8 cerebral hemorrhage 32 occasional (7.5%) HP:0001342
9 ascites 32 occasional (7.5%) HP:0001541
10 thrombocytopenia 32 occasional (7.5%) HP:0001873
11 leukopenia 32 occasional (7.5%) HP:0001882
12 fever 32 hallmark (90%) HP:0001945
13 diarrhea 32 occasional (7.5%) HP:0002014
14 nausea and vomiting 32 occasional (7.5%) HP:0002017
15 abdominal pain 32 frequent (33%) HP:0002027
16 gastrointestinal hemorrhage 32 occasional (7.5%) HP:0002239
17 hepatomegaly 32 occasional (7.5%) HP:0002240
18 headache 32 hallmark (90%) HP:0002315
19 hypotension 32 occasional (7.5%) HP:0002615
20 arthralgia 32 frequent (33%) HP:0002829
21 hypoproteinemia 32 occasional (7.5%) HP:0003075
22 cardiorespiratory arrest 32 occasional (7.5%) HP:0006543

UMLS symptoms related to Dengue Disease:


fever, pruritus

MGI Mouse Phenotypes related to Dengue Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 THPO VCAM1 CCL5 CD40LG FCGR1A ICAM1
2 immune system MP:0005387 9.32 RAF1 THPO VCAM1 CCL5 CD40LG FCGR1A

Drugs & Therapeutics for Dengue Disease

Drugs for Dengue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
2
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
3
Histamine Phosphate Phase 4 51-74-1 65513
4 Neurotransmitter Agents Phase 4
5 Histamine Antagonists Phase 4
6 Histamine H1 Antagonists Phase 4
7 Dermatologic Agents Phase 4
8 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Anti-Allergic Agents Phase 4
10 Antipruritics Phase 4
11
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3,Not Applicable 70288-86-7 6474909
12 DEET Phase 3
13 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
14 Insect Repellents Phase 3
15 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
16 Protective Agents Phase 3
17 Antiparasitic Agents Phase 2, Phase 3,Phase 1,Not Applicable
18 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
19
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
20
Ribavirin Approved Phase 2 36791-04-5 37542
21
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
22
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
23 Chloroquine diphosphate Phase 1, Phase 2 50-63-5
24 Analgesics Phase 1, Phase 2,Not Applicable
25 Cortisol succinate Phase 2
26 Analgesics, Non-Narcotic Phase 1, Phase 2,Not Applicable
27 Anthelmintics Phase 1, Phase 2
28 Hydrocortisone 17-butyrate 21-propionate Phase 2
29 Hydrocortisone acetate Phase 2
30 Peripheral Nervous System Agents Phase 1, Phase 2,Not Applicable
31 Antiprotozoal Agents Phase 1, Phase 2,Not Applicable
32 Anti-Inflammatory Agents Phase 1, Phase 2,Not Applicable
33 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2,Not Applicable
34 Antimalarials Phase 1, Phase 2,Not Applicable
35 Antirheumatic Agents Phase 1, Phase 2,Not Applicable
36 Antimetabolites Phase 2
37 Antiviral Agents Phase 2
38 Coagulants Phase 2
39 Hemostatics Phase 2
40 Antibodies Phase 1, Phase 2,Phase 2,Not Applicable
41 Immunoglobulins Phase 1, Phase 2,Phase 2,Not Applicable
42
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
43
Aluminum sulfate Approved Phase 1 10043-01-3
44 Papaya Approved, Nutraceutical Phase 1
45 Adjuvants, Immunologic Phase 1
46 Gastrointestinal Agents Phase 1
47 Antacids Phase 1
48 Anti-Ulcer Agents Phase 1
49
Albendazole Approved, Vet_approved Not Applicable 54965-21-8 2082
50
Artesunate Approved, Investigational Not Applicable 88495-63-0 6917864 5464098

Interventional clinical trials:

(show top 50) (show all 183)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) Recruiting NCT02555072 Phase 4
3 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Unknown status NCT01374516 Phase 3
4 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Unknown status NCT01373281 Phase 3
5 Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
6 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
7 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
8 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
9 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
10 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
11 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
12 Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines Completed NCT00735644 Phase 3
13 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
14 Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV Completed NCT01190228 Phase 3
15 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) Recruiting NCT03341637 Phase 3
16 Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine Recruiting NCT02406729 Phase 3
17 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults Recruiting NCT03342898 Phase 3
18 Study of INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS) Recruiting NCT03037164 Phase 3
19 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
20 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
21 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
22 Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue Active, not recruiting NCT03423173 Phase 3
23 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3 TDV Placebo
24 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine Not yet recruiting NCT03525119 Phase 3
25 The Effect of Chloroquine in the Treatment of Patients With Dengue Unknown status NCT00849602 Phase 1, Phase 2 Placebo;Chloroquine
26 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
27 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
28 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
29 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
30 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
31 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
32 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
33 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
34 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
35 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
36 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
37 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
38 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
39 A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children Completed NCT01843621 Phase 1, Phase 2
40 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Tetravalent Dengue Vaccine (TDV) in Adults in Singapore Completed NCT02425098 Phase 2
41 Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
42 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
43 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
44 A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults Completed NCT00239577 Phase 2
45 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
46 Celgosivir as a Treatment Against Dengue Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
47 A Phase II Trial of a WRAIR Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults Completed NCT00350337 Phase 2
48 A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand Completed NCT00370682 Phase 2
49 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
50 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Completed NCT00468858 Phase 2

Search NIH Clinical Center for Dengue Disease

Cochrane evidence based reviews: dengue

Genetic Tests for Dengue Disease

Anatomical Context for Dengue Disease

MalaCards organs/tissues related to Dengue Disease:

41
Skin, Testes, Bone, Eye, Heart, Endothelial, Thyroid

Publications for Dengue Disease

Articles related to Dengue Disease:

(show top 50) (show all 264)
# Title Authors Year
1
Epidemiological trends and risk factors associated with dengue disease in Pakistan (1980-2014): a systematic literature search and analysis. ( 29907109 )
2018
2
Joint ancestry and association test indicate two distinct pathogenic pathways involved in classical dengue fever and dengue shock syndrome. ( 29447178 )
2018
3
Models to assess the effects of non-identical sex ratio augmentations of Wolbachia-carrying mosquitoes on the control of dengue disease. ( 29530790 )
2018
4
Dynamics of dengue disease with human and vector mobility. ( 29751893 )
2018
5
Post Dengue Fever Epidural abscess with or without Spondylodiscitis-a Case series of 8 patients in a single season in a single Centre: Do the dengue has a predilection for the Neural tissue? ( 29979359 )
2018
6
Spatial-Temporal Analysis of Dengue Fever and Hemorrhagic Fever in Mexico from 1995-2015. ( 29402463 )
2018
7
Travel-acquired Scrub Typhus Infection Masked by Dengue Fever in a Patient from Nonendemic Area. ( 29910575 )
2018
8
Ocular manifestations of emerging arboviruses: Dengue fever, Chikungunya, Zika virus, West Nile virus, and yellow fever. ( 29929827 )
2018
9
Vitamin D serostatus and dengue fever progression to dengue hemorrhagic fever/dengue shock syndrome. ( 28903788 )
2017
10
Bayesian dynamic modeling of time series of dengue disease case counts. ( 28671941 )
2017
11
Modeling Impact of Temperature and Human Movement on the Persistence of Dengue Disease. ( 29312458 )
2017
12
Effect of Rainfall for the Dynamical Transmission Model of the Dengue Disease in Thailand. ( 28928793 )
2017
13
Cardiac tamponade in a patient with severe dengue fever. ( 29160522 )
2017
14
Relative risk estimation of dengue disease at small spatial scale. ( 28810908 )
2017
15
Optical coherence tomography angiography features of acute macular neuroretinopathy in dengue fever. ( 29133664 )
2017
16
Epidemiological characteristics of dengue disease in Saurashtra region, India, during year 2015. ( 29302526 )
2017
17
Correlation of altered expression of a long non-coding RNA, NEAT1, in peripheral blood mononuclear cells with dengue disease progression. ( 29031635 )
2017
18
Pattern Of Presentation Among Adults Hospitalized With Dengue Disease. ( 29076677 )
2017
19
Dengue fever presenting as cauda equina syndrome. ( 28739570 )
2017
20
Dual infection with Japanese encephalitis and dengue fever: Issues with diagnosis. ( 28084252 )
2017
21
Serum cytokine/chemokine profiles in patients with dengue fever (DF) and dengue hemorrhagic fever (FHD) by using protein array. ( 28242509 )
2017
22
Transcriptional Profiling Confirms the Therapeutic Effects of Mast Cell Stabilization in a Dengue Disease Model. ( 28659489 )
2017
23
Dengue fever triggering hemiconvulsion hemiplegia epilepsy in a child. ( 28488637 )
2017
24
Epidemiological Characteristics of Dengue Disease in Latin America and in the Caribbean: A Systematic Review of the Literature. ( 28392806 )
2017
25
Myelitis and cauda equina involvement following dengue fever. A case report and review of the literature. ( 29294422 )
2017
26
Trends of Dengue Disease Epidemiology. ( 28579763 )
2017
27
Antibody-dependent enhancement of severe dengue disease in humans. ( 29097492 )
2017
28
Potential Risk Areas of Aedes albopictus in South-Eastern Iran: A Vector of Dengue Fever, Zika, and Chikungunya. ( 28928720 )
2017
29
Anterior ischemic optic neuropathy following dengue fever. ( 27843231 )
2016
30
A rare case of an 8-month-old child with dengue fever complicated by acute diffuse transverse myelitis. ( 27857814 )
2016
31
Acute Posterior Multifocal Placoid Pigment Epitheliopathy Following Dengue Fever: A New Association for an Old Disease. ( 26902823 )
2016
32
Dengue Disease Modelling and Forecasting: Utility and Limitations. ( 27292001 )
2016
33
Dengue fever associated with extreme reactive thrombocytosis ( 28078838 )
2016
34
High degree atrioventricular block with ventricular asystole in a case of dengue fever. ( 27751287 )
2016
35
Unusual Presentation of Dengue Fever: A child with acute myocarditis. ( 26909198 )
2016
36
Relative Contribution of Dengue IgG Antibodies Acquired during Gestation or Breastfeeding in Mediating Dengue Disease Enhancement and Protection in Type I Interferon Receptor-Deficient Mice. ( 27341339 )
2016
37
Early diagnosis of dengue disease severity in a resource-limited Asian country. ( 27670906 )
2016
38
Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease. ( 27506852 )
2016
39
Isolated unilateral sixth cranial nerve palsy: A rare presentation of dengue fever. ( 28461846 )
2016
40
Stuck with pancytopenia in dengue fever: Evoke for hemophagocytic syndrome. ( 26955219 )
2016
41
Dengue fever with diffuse cerebral hemorrhages, subdural hematoma and cranial diabetes insipidus. ( 27165581 )
2016
42
A case of acalculous cholecystitis in the course of dengue fever in a traveller returned from Brazil. ( 27029928 )
2016
43
Mannose-binding lectin gene (MBL2) polymorphisms related to the mannose-binding lectin low levels are associated to dengue disease severity. ( 27180198 )
2016
44
Dengue Fever Presenting Atypically with Viral Conjunctivitis and Subacute Thyroiditis. ( 27376214 )
2016
45
Dengue Fever-Associated Maculopathy and Panuveitis in Australia. ( 28078150 )
2016
46
Guillain-BarrAc syndrome and dengue fever: report on ten new cases in Brazil. ( 27992005 )
2016
47
Co-infection of dengue fever and hepatitis A in a Russian traveler. ( 27516967 )
2016
48
Hypokalemia in dengue fever- A descriptive study. ( 27727941 )
2016
49
Symptomatic Dengue Disease in Five Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial. ( 27532617 )
2016
50
Central retinal vein occlusion concomitant with dengue fever. ( 27847619 )
2016

Variations for Dengue Disease

Expression for Dengue Disease

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Disease patients vs. healthy controls: 35 (show top 50) (show all 93)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 4.85 0.000
2 RRM2 ribonucleotide reductase M2 Blood + 4.48 0.000
3 CEP55 centrosomal protein 55kDa Blood + 4.33 0.000
4 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.30 0.000
5 XIST X inactive specific transcript (non-protein coding) Blood - 4.25 0.009
6 CD38 CD38 molecule Blood + 4.23 0.000
7 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 Blood + 4.10 0.000
8 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.08 0.000
9 IGHM immunoglobulin heavy constant mu Blood + 4.04 0.000
10 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.99 0.000
11 SHCBP1 SHC SH2-domain binding protein 1 Blood + 3.97 0.000
12 PBK PDZ binding kinase Blood + 3.97 0.000
13 TYMS thymidylate synthetase Blood + 3.96 0.000
14 PI3 peptidase inhibitor 3, skin-derived Blood - 3.93 0.000
15 CDCA2 cell division cycle associated 2 Blood + 3.91 0.000
16 SESN3 sestrin 3 Blood - 3.90 0.000
17 HMMR hyaluronan-mediated motility receptor (RHAMM) Blood + 3.83 0.000
18 MKI67 marker of proliferation Ki-67 Blood + 3.83 0.000
19 ZWINT ZW10 interacting kinetochore protein Blood + 3.83 0.000
20 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) Blood + 3.80 0.000
21 CDK1 cyclin-dependent kinase 1 Blood + 3.78 0.000
22 NCAPG non-SMC condensin I complex, subunit G Blood + 3.76 0.000
23 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.76 0.000
24 SPC25 SPC25, NDC80 kinetochore complex component Blood + 3.75 0.000
25 CDC20 cell division cycle 20 Blood + 3.73 0.000
26 CNTNAP3 contactin associated protein-like 3 Blood - 3.72 0.000
27 TOP2A topoisomerase (DNA) II alpha Blood + 3.71 0.000
28 NOV nephroblastoma overexpressed Blood - 3.71 0.000
29 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood + 3.69 0.015
30 CCNB2 cyclin B2 Blood + 3.62 0.000
31 CDKN3 cyclin-dependent kinase inhibitor 3 Blood + 3.62 0.000
32 KIAA0101 KIAA0101 Blood + 3.61 0.000
33 KIF2C kinesin family member 2C Blood + 3.60 0.000
34 TK1 thymidine kinase 1, soluble Blood + 3.59 0.000
35 RPS4Y1 ribosomal protein S4, Y-linked 1 Blood + 3.57 0.017
36 TTK TTK protein kinase Blood + 3.56 0.000
37 CDC6 cell division cycle 6 Blood + 3.56 0.000
38 CAV1 caveolin 1, caveolae protein, 22kDa Blood + 3.56 0.000
39 CENPA centromere protein A Blood + 3.54 0.000
40 CYAT1 immunoglobulin lambda light chain-like Blood + 3.52 0.000
41 ASPM abnormal spindle microtubule assembly Blood + 3.52 0.000
42 OR2W3 olfactory receptor, family 2, subfamily W, member 3 Blood - 3.51 0.000
43 UHRF1 ubiquitin-like with PHD and ring finger domains 1 Blood + 3.50 0.000
44 SELENBP1 selenium binding protein 1 Blood - 3.50 0.000
45 GINS2 GINS complex subunit 2 (Psf2 homolog) Blood + 3.49 0.000
46 MELK maternal embryonic leucine zipper kinase Blood + 3.47 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.47 0.000
48 CHEK1 checkpoint kinase 1 Blood + 3.46 0.000
49 CCNB1 cyclin B1 Blood + 3.45 0.000
50 KIF11 kinesin family member 11 Blood + 3.42 0.000
Search GEO for disease gene expression data for Dengue Disease.

Pathways for Dengue Disease

Pathways related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 CCL5 CD209 CD40LG FCGR1A ICAM1 IL11
2
Show member pathways
13.22 CD209 CD40LG FCGR1A ICAM1 PTPN11 RAF1
3
Show member pathways
12.97 CCL5 CD40LG FCGR1A ICAM1 IL11 PTPN11
4
Show member pathways
12.45 IL11 PTPN11 RAF1 THPO
5
Show member pathways
12.36 FCGR1A ICAM1 PTPN11 VCAM1
6
Show member pathways
12.32 CCL5 CD209 HCFC1 ICAM1 PTPN11 RAF1
7
Show member pathways
12.17 ICAM1 PTPN11 RAF1 VCAM1
8 11.95 CD40LG ICAM1 VCAM1
9 11.9 IL11 THPO VCAM1
10 11.83 CD209 IL11 THPO
11 11.79 CCL5 ICAM1 VCAM1
12
Show member pathways
11.78 CCL5 ICAM1 IL11 PTPN11 THPO
13 11.75 CD40LG FCGR1A ICAM1 VCAM1
14 11.71 FCGR1A IL11 THPO
15 11.69 CD40LG ICAM1 VCAM1
16 11.64 CCL5 ICAM1 IL11
17
Show member pathways
11.43 CD40LG ICAM1 VCAM1
18 11.36 FCGR1A ICAM1 MBL2
19 11.27 CD40LG ICAM1 VCAM1
20 10.95 CD209 RAF1
21 10.9 ICAM1 PTPN11 RAF1 VCAM1
22 10.79 ICAM1 VCAM1
23 10.57 ICAM1 IL11 PTPN11 RAF1

GO Terms for Dengue Disease

Cellular components related to Dengue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CCL5 CD40LG ICAM1 IL11 MBL2 THPO
2 cell surface GO:0009986 9.35 CD209 CD40LG ICAM1 MBL2 VCAM1
3 external side of plasma membrane GO:0009897 8.92 CD209 CD40LG ICAM1 VCAM1

Biological processes related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cellular response to tumor necrosis factor GO:0071356 9.71 CCL5 ICAM1 VCAM1
2 regulation of immune response GO:0050776 9.71 CD40LG FCGR1A ICAM1 VCAM1
3 platelet activation GO:0030168 9.7 CD40LG PTPN11 RAF1
4 cytokine-mediated signaling pathway GO:0019221 9.65 CCL5 ICAM1 IL11 PTPN11 VCAM1
5 B cell differentiation GO:0030183 9.63 CD40LG IL11 VCAM1
6 interferon-gamma-mediated signaling pathway GO:0060333 9.61 FCGR1A ICAM1 VCAM1
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 CCL5 ICAM1 PTPN11 RAF1 THPO
8 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.54 CD209 ICAM1 VCAM1
9 neurotrophin TRK receptor signaling pathway GO:0048011 9.51 PTPN11 RAF1
10 regulation of protein complex assembly GO:0043254 9.49 HCFC1 PTPN11
11 negative regulation of hormone secretion GO:0046888 9.48 IL11 PTPN11
12 membrane to membrane docking GO:0022614 9.32 ICAM1 VCAM1
13 positive regulation of T cell proliferation GO:0042102 9.26 CCL5 CD209 CD40LG VCAM1
14 leukocyte cell-cell adhesion GO:0007159 9.02 CCL5 CD209 CD40LG ICAM1 VCAM1

Molecular functions related to Dengue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mannose binding GO:0005537 8.96 CD209 MBL2
2 cytokine activity GO:0005125 8.92 CCL5 CD40LG IL11 THPO

Sources for Dengue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....